Advanced Workshop on CAR-T Therapy: Oncology and Beyond

• Understand the fundamentals of CAR-T cell biology and immunotherapy mechanisms.
• Explore CAR-T therapy applications in oncology and beyond.
• Learn about the latest innovations, clinical trials, and emerging applications.
• Gain knowledge of CAR-T cell manufacturing and regulatory requirements.
• Discuss ethical, safety, and scalability challenges in CAR-T therapy.

Day 1: Introduction to CAR-T Therapy

Workshop Overview 

• Introduction to the workshop structure and objectives
• Importance of CAR-T therapy in modern oncology

Introduction to Immunotherapy 

• What is immunotherapy?
• The role of the immune system in cancer treatment
• Overview of different immunotherapy approaches (Monoclonal antibodies, checkpoint inhibitors, CAR-T)

CAR-T Therapy Basics

• What is CAR-T (Chimeric Antigen Receptor T-cell) therapy?
• Mechanism of CAR-T: How it works (T-cell modification and cancer cell targeting)
• Historical development of CAR-T therapy
• Overview of FDA-approved CAR-T therapies (e.g., Kymriah, Yescarta, Breyanzi)

The Science Behind CAR-T 

• T-cell biology and role in immune response
• CAR-T cell structure and function: Antigen recognition, CAR components
• Process of CAR-T cell therapy (from patient cell collection to infusion)

Clinical Indications of CAR-T Therapy

• Types of cancers treated with CAR-T (leukemia, lymphoma, etc.)
• Patient selection and eligibility criteria
• Success rates and key clinical outcomes

Q&A and Recap

• Open floor for questions
• Summary of key learnings from Day 1

Day 2: CAR-T Therapy Manufacturing and Clinical Applications

Recap of Day 1 and Key Takeaways

• Brief review of the fundamentals of CAR-T therapy

CAR-T Manufacturing Process

• Overview of the CAR-T cell production process
• Steps: T-cell collection, genetic modification (viral vectors), CAR-T expansion, and infusion
• Challenges in manufacturing (scalability, cost, and logistics)
• Ensuring safety and efficacy during production
• Automation and emerging trends in CAR-T manufacturing

Clinical Administration of CAR-T Therapy

• Patient preparation: Lymphodepleting chemotherapy
• The CAR-T infusion process
• Managing side effects and toxicities: Cytokine Release Syndrome (CRS), Neurotoxicity
• CAR-T monitoring and patient management post-infusion
• Long-term follow-up and remission rates

Real-World Case Studies

• Analysis of real-world CAR-T patient outcomes (success stories and challenges)
• Discussion of clinical trials and their significance in CAR-T advancements
• Case study presentations with interactive Q&A

Q&A and Recap 

• Address any questions
• Summarize the session learnings

Day 3: Future Directions, Challenges, and Ethical Considerations

Recap of Day 2 and Key Takeaways

• Brief review of the CAR-T manufacturing and clinical process

Advancements and Innovations in CAR-T

• Next-generation CAR-T therapies: Dual-targeting CARs, armored CARs, and universal CAR-T cells
• CAR-NK and other cellular therapies in development
• Use of CAR-T beyond hematologic malignancies (solid tumors)
• Emerging technology: CRISPR and gene editing in CAR-T optimization

Overcoming Current Challenges

• Resistance to CAR-T therapy and relapse in patients
• Addressing high costs and accessibility issues
• Managing side effects more effectively
• Overcoming the complexity of treating solid tumors

Ethical and Regulatory Considerations

• Ethical challenges in gene-modified therapies (access, cost, and equity)
• Informed consent and patient education
• Regulatory pathways for CAR-T approval (FDA, EMA)
• Impact of CAR-T on the healthcare system (insurance coverage, cost of care)

Future of CAR-T: Looking Ahead

• Predictions for the next 5–10 years in CAR-T therapy
• Personalized medicine and the integration of AI and data in CAR-T treatment
• Potential for CAR-T in combination therapies

Open Discussion and Q&A

• Group discussion on the future of CAR-T
• Audience questions and expert responses

Conclusion and Wrap-Up 

• Recap of the entire 3-day workshop
• Final thoughts and takeaways

• Undergraduate or graduate degree in Biotechnology, Immunology, Biomedical Sciences, or related fields.
• Medical professionals, oncologists, and clinical researchers involved in cell-based therapies.
• Individuals with an interest in gene therapy, cellular therapies, or advanced medical treatments.